MDGL earnings analysis
What we found in MDGL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Madrigal Pharmaceuticals reported Q1 2026 financials with strong revenue growth, achieving $311.3 million, reflecting a 127% increase from Q1 2025's $137.3 million. The company recorded a net loss of $94.4 million, up from $73.2 million in the year-ago period, while expanding its cash position to $817.9 million despite significant operating costs related to the commercialization of its product Rezdiffra. Management remains optimistic about the adoption and growth potential of Rezdiffra in the market.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Accelerates
- Q1 2026 revenue was $311.3 million, a 127% increase from $137.3 million in Q1 2025.
- Improving Cash Position
- Cash and cash equivalents increased to $227.0 million from $198.7 million quarter-over-quarter.
- Strong Adoption of Rezdiffra
- Product sales of Rezdiffra significantly drove the revenue increase, resulting in a strong market presence.
- Segment Performance
- Research and Development expenses surged 146% to $108.7 million attributed to pipeline expansion.
- Lower Losses Per Share
- Reported EPS loss of $3.25, improved from a loss of $2.61 in Q1 2025.
- Operating Cash Flow Trends
- Net cash used in operating activities reached $167.4 million, reflecting increased spending on commercialization.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Operating Expenses
- Operating expenses rose to $404.1 million from $216.6 million in Q1 2025, indicating cost challenges.
- Significant Losses Persist
- Net loss increased by 29% year-over-year, now at $94.4 million for Q1 2026.
- Dependence on Rezdiffra Adoption
- Continued losses and financing needs hinge on successful market uptake of Rezdiffra.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-3.25
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MDGL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever